Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2006)
41 slides from Genetic Technologies's shareholder meeting presentation, Nov 17, 2006
Slide 1: ASX Announcement: 2006 Annual General Meeting
genetic technologies ASX ANNOUNCEMENT November 17'", 2006 2006 Annual General Meeting Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered at the Company's 2006 Annual General Meeting to be held at 11.00 am this morn
Slide 2: Genetic Technologies Limited Annual General Meeting
Genetic Technologies Limited Annual General Meeting Friday, November 17*, 2006 Melbourne Museum Delivering the benefits of the genetic revolution genetic technologies
Slide 3: Resolution 1 — Consideration of financial statements
genetic technologies Resolution 1 — Consideration of financial statements To receive and consider the Financial Report, Directors’ Report and Auditor's Report for the year ended 30 June 2006. No vote required
Slide 4: Resolution — Re-election of Mr. Robert Edge
genetic technologies Resolution 2 — Re-election of Mr. Robert Edge To re-elect Mr. Robert J. Edge who retires by rotation in accordance with the Company’s Constitution and being eligible offers himself for re-election as a Director. Mr. Edge has advised that he does not seek re-election and, accordi
Slide 5: Resolution — Remuneration Report
genetic technologies Resolution 3 — Remuneration Report That the Remuneration Report section of the Director's Report for the Company for the year ended 30 June 2006 be adopted. Proxy votes received For: 26,631,072 Against: 241,440 To Chairman: 16,867,292 To others: 164,173,954 Abstain: 23,100
Slide 6: Presentation by Dr. Mervyn Jacobson, CEO
Genetic Technologies Limited Annual General Meeting Presentation by Dr. Mervyn Jacobson Chief Executive Officer Delivering the benefits of the genetic revolution
Slide 7: Safe Harbour Disclaimer
genetic technologies Safe Harbour Disclaimer Some of the statements made in this presentation are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations fo
Slide 8: Who are we?
Who are we? genetic technologies We are an Australian life sciences company: * . . Founded in 1989 as GeneType, to research non-coding (“junk”) DNA Research led to ground-breaking inventions on relevance of non-coding DNA Resulted in broad “gateway” patents, applicable to all genes, in all species T
Slide 9: Who are we?
Who are we? genetic technologies Today, we remain focussed on: . . Further fundamental Research in molecular biology and in cellular behaviour, and Bringing our discoveries to the market - via Licensing and new Genetic Tests In summary, we have 3 distinct Business Units: Research, Licensing & Testin
Slide 10: We continue to believe in the vast future potential of Biotech
genetic technologies We continue to believe in the vast future potential of Biotech: * The US pharmaceutical industry now spends more than $US3B/year on research in genomics & personalised medicine, (representing 10-20% of total R&D spend) * Such research received a huge boost in 2001, from the Huma
Slide 11: Research and the "Cycle of Invention"
genetic technologies X Research and the “Cycle of Invention” - the fundamental culture at GTG * Research leads to Inventions * Inventions lead to Patents * Patents lead to Licenses * Licenses lead to Revenues * Revenues lead to more Research ... * Patents can result in very substantial revenues — pr
Slide 12: History of the Non-Coding Patents
genetic technologies History of the Non-Coding Patents GTG lists seneType AG on ASX formed Patents issued Six legal challenges resolved in G/G s favour Current issued a | Patent ——_—__| patents expirg insurance Patents lodged “\ GENE lists on NASDAQ ‘89 ‘90 ‘93 ‘96 ‘98 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 15
Slide 13: The Licensing Program at GTG
The Licensing Program at GTG * PAST — 32 licenses (27 commercial and 5 research) — $60M in total value — More than $2M per annum in recurring revenues * PRESENT — 2,500 leads identified — 400 deemed “commercially significant” — 43 active negotiations now underway — 5 licensing teams ¢ FUTURE — Total
Slide 14: Licensing results so far
genetic technologies Licensing results so far GTG’s patents are now seen to have great strategic and commercial value, as the scientific community continues to discover new significance for non- coding DNA, within the genomes of all species. Ref: “Nature”, November 9", 2006 __ Average Annual Value
Slide 15: NEWS
NEWS one who has ever put to bly furniture Knows that ‘havi pathy olution, directing the F our genome t do in other organisms. 30-year-old hy, pothesis thaty gene regulation — not the crea- the traits that the changed rapidly in human ased on the theory that they are most likely to have shaped our d
Slide 16: Licensing — Famous quotes when our patents were granted
genetic technologies Licensing — Famous quotes when our patents were granted “Why should we all have to pay for one company’s bright idea?” - “New Scientist’, UK, May 2002 (referring to the GTG patents)
Slide 17: Licensing - The Price of Success
genetic technologies Licensing - The Price of Success Junkyard Dogs FORBES MAGAZINE, USA - 2003
Slide 18: Licensing - Famous Quotes
genetic technologies Licensing - Famous Quotes “DNA has two types of digital information — the genes that encode proteins and the gene regulatory networks”. “The digital code of DNA” - Leroy Hood and David Galas, “Nature”, January 2003
Slide 19: Licensing - Famous Quotes
genetic technologies Licensing - Famous Quotes “The failure of biologists to consider the massive amounts of transcription involving non-coding DNA and the Genome will be regarded as perhaps the biqgest mistake in the history of biology”. - Professor John Mattick, February 2003
Slide 20: Famous quotes — in 2003
genetic technologies Famous quotes — in 2003 “Gene patents: Pathologists call on Governments to challenge GTG” - “Australian Biotechnology News”, May 2003 Which then led to emotive features on Australian TV, including: — Four Corners — 60 Minutes — Seven Thirty Report — Catalyst — etc.
Slide 21: Three years later: Int. Congress on Human Genetics, August '04
genetic technologies Three years later: 11 Int. Congress on Human Genetics, August ’04 GTG was invited to be a lead sponsor of the whole Congress.
Slide 22: Human Genetics Society of Australasia letter
Human Generics SocieTy or AUSTRALASIA VICTORIAN BRANCH 4” October 2006 Dr Mervyn Jacobson Chi scutive Officer Genetic Technologies Limited P.O. Box 118 FITZROY VIC 3065 Dear Mervyn, | am writing to thank you for your sponsership of the Human Genetics Society of Australasia (HGSA), Annual General Mee
Slide 23: Paternity Diagnostics
Paternity Diagnostics Genetic Testing ee a , Intellectual Property GTG R&D Licensees
Slide 24: Genetic Testing - Overview
Genetic Testing genetic technologies - Overview * . * Australia’s largest independent DNA testing laboratory Australia’s No. 1 paternity testing laboratory (60% of the market) First private laboratory to receive forensics accreditation Profitability and growing market share are driven by ongoing dev
Slide 25: Genetic Testing - Paternity Testing
genetic technologies Genetic Testing - Paternity Testing « Australia’s No.1 paternity testing laboratory (60% of market) « [n 2006, we won a welfare tender to perform DNA testing re disputed paternity « Also in 2006, we expanded our paternity testing business to China
Slide 26: Genetic Testing - Medical Diagnostics
genetic technologies Genetic Testing - Medical Diagnostics ¢ Only laboratory in Asia-Pacific region to be allowed to legally perform the Myriad BRCA tests * Only member of GENDIA in Asia-Pacific region « Additional accreditation now received from NATA for “complex genetic tests * Starting to receive
Slide 27: Genetic Testing - Forensics
genetic technologies Genetic Testing - Forensics ¢ First independent lab in Australia to be accredited to perform forensic testing ¢ Only independent lab in Australia to win a State government contract —-a NSV Police outsourcing trial, which was completed on schedule in August 2006 « NSW Police Mini
Slide 28: Genetic Testing - Animal Testing
Genetic Testing genetic technologies ~ Animal Testing * GTG now has unique rights to perform a range of valuable genetic tests on animals, including for cattle and dogs (MetaMorphix), dogs (Optigen) etc., establishing a leading position in genetic testing of animals in Australia GTG has been appoint
Slide 29: Slide 29
Slide 30: MycroLab — the future of genetic testing
genetic technologies MycroLab — the future of genetic testing ° GTG and MycroLab have reached agreement to collaborate on the development and distribution of a number of new tests, to be analysed on the MycroLab platform This is a small hand-held device - the size of a mobile phone - or in some case
Slide 31: Research — Overview — significant research projects
genetic technologies Research — Overview — 5 significant research projects: ° RareCellect® — Non-invasive separation of foetal cells from maternal blood Pathogens — treating livestock parasites in an entirely new way ImmunAid — identifying the cycle in the immune system to allow more effective treat
Slide 32: Research - RareCellect
Research - RareCellect® Identifies and separates foetal cells from peripheral (venous) maternal blood May be performed as early as 8 weeks pregnancy Foetal cells then used for prenatal testing (Down’s syndrome, etc.) Eliminates all invasive and risky procedures (amniocentesis, CVS, etc.) GTG has wor
Slide 33: Research - PGGP
Research - PGGP Traditional raditionally the host is medicated to destroy the PGGP delivers a compound to the parasite arasite. Side effects harm (i) the host, (ii) the rendering it sterile. The host is unaffected. onsumers of milk/meat and (iii) the environment Could eliminate current wastage of $b
Slide 34: Research — ImmunAid
genetic technologies Research — ImmunAid New understandings re the immune system’s response to disease Immune Cycle Time * Concept - to administer treatment at more relevant “windows” in the cycle * HIV and cancer monitoring trials already undertaken in last two years * This year - cycle now proven
Slide 35: In 2006, we restructured our Senior Management Team
genetic technologies In 2006, we restructured our Senior Management Team Board of Directors Dr. Mervyn Jacobson Chief Executive Officer Tom Howitt Geoff Newing Gary Cobon CFO coo cso
Slide 36: In 2006, we restructured our Scientific Advisory Committee
genetic technologies In 2006, we restructured our Scientific Advisory Committee * Professor Colin Masters — Professor of Pathology and Laureate Professor at University of Melbourne (Convenor) « Professor Norbert Bachl - Dean of the Faculty Sports Science and University Sports at the University of Vi
Slide 37: In 2006 — highlights
genetic technologies In 2006 « Continued to build infra-structure of our management team, our SAC and our Board « Were invited to become a lead sponsor to the International Congress on Human Genetics in Brisbane, Australia, in August 2006 * Were invited guest at the 1st European Conference on Anti-A
Slide 38: In 2006 — Licensing
In 2006 — Licensing * Settled the law suit against Applera, on terms favourable to GTG ¢ Significantly expanded our licensing program. GTG has 5 active teams globally * Granted additional licenses: — re dogs to Optigen, USA — re cattle in Bovigen, USA — re human testing to Innogenetics, Belgium — Pl
Slide 39: In 2006 — Genetic Testing
genetic technologies In 2006 — Genetic Testing We expanded our genetic testing business — in both scope and sales We won a Government tender to assist State police with their forensic testing We were granted a number of additional accrecitations by “NATA” We received significant new referrals from G
Slide 40: Thanks to GTG
genetic technologies Thanks to GTG: * There are now 50 rare Brush-tailed Rock Wallabies in captivity * There are now 11 pairs in active breeding programs * First ever release now planned for December 6" in the Grampians.
Slide 41: Dr. Mervyn Jacobson, Chief Executive Officer
Dr. Mervyn Jacobson Chief Executive Officer genetic technologies Delivering the benefits of the genetic revolution
Genetic Technologies — Shareholder Meeting (November 2006) on 6ix